Health ❯ Healthcare ❯ Patient Outcomes

Disease-Free Survival

Recurrence Rates Adjuvant Therapy Recurrence Risk Invasive Disease-Free Survival Overall Survival Rates Phase 2 Trials Clinical Guidelines Cancer Recurrence Clinical Efficacy

FDA Accepts Roche’s Tecentriq for Priority Review in dMMR Stage III Colon Cancer

Approval by October 9, 2026 would establish the first immunotherapy-based adjuvant option for patients with dMMR/MSI-H stage III colon cancer.

Transgene Completes Phase 2 Randomization for Personalized Cancer Vaccine TG4050

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

EU Regulators Back Libtayo as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

Atezolizumab-Enhanced Chemotherapy Halves Recurrence in Stage III dMMR Colon Cancer